(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Rani Therapeutics Holdings's earnings in 2026 is -$28,315,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$35,323,416, with the lowest RANI earnings forecast at -$70,257,996, and the highest RANI earnings forecast at -$22,965,689. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$37,498,474, with the lowest RANI earnings forecast at -$77,402,876, and the highest RANI earnings forecast at -$16,586,331.
In 2028, RANI is forecast to generate -$58,252,651 in earnings, with the lowest earnings forecast at -$97,646,706 and the highest earnings forecast at -$15,310,459.